Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach. In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administration of the alemtuzumab treatment. Adverse events were observed in 45,7% of the patients. These events were ranked as severe in 23% of the patients. We reported, in particular, cases of autoimmune hemolytic anemia (AIHA), pancytopenia, viral hepatitis E and noninfectious meningo-encephalomyelitis.

di Ioia M., Di Stefano V., Farina D., Di Tommaso V., Travaglini D., Pietrolongo E., et al. (2020). Data of safety in a single-center alemtuzumab treated population. DATA IN BRIEF, 29, 1-3 [10.1016/j.dib.2020.105341].

Data of safety in a single-center alemtuzumab treated population

Di Stefano V.
Secondo
Conceptualization
;
2020-04

Abstract

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach. In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administration of the alemtuzumab treatment. Adverse events were observed in 45,7% of the patients. These events were ranked as severe in 23% of the patients. We reported, in particular, cases of autoimmune hemolytic anemia (AIHA), pancytopenia, viral hepatitis E and noninfectious meningo-encephalomyelitis.
Settore MED/26 - Neurologia
https://www.sciencedirect.com/science/article/pii/S2352340920302353?via=ihub
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062935/
di Ioia M., Di Stefano V., Farina D., Di Tommaso V., Travaglini D., Pietrolongo E., et al. (2020). Data of safety in a single-center alemtuzumab treated population. DATA IN BRIEF, 29, 1-3 [10.1016/j.dib.2020.105341].
File in questo prodotto:
File Dimensione Formato  
Data of safety in a single-center alemtuzumab treated population.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 180.7 kB
Formato Adobe PDF
180.7 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/520469
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact